Sarcopenia

Immunis Partners with Japanese Drug Company Toray to Reverse Sarcopenia

Retrieved on: 
Mittwoch, Mai 22, 2024
Research, Infectious Diseases, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Partnership, Textile, Metabolism, Global health, DSM-IV codes, Itch, Sarcopenia, Human, Multimedia, Notifiable disease, Quality of life, Electronics, Dietary supplement

Immunis, Inc., a clinical-stage biotech developing innovative secretome therapies to address age-related disease and immune dysfunction, obtained a significant strategic milestone in partnering with Toray , a Japanese drug company part of the Toray Group .

Key Points: 
  • Immunis, Inc., a clinical-stage biotech developing innovative secretome therapies to address age-related disease and immune dysfunction, obtained a significant strategic milestone in partnering with Toray , a Japanese drug company part of the Toray Group .
  • With its production of various advanced material sciences, Toray has diversified expertise in industries including pharmaceuticals, electronics, textiles, and aerospace.
  • Both Immunis and Toray operate with the mission of advancing human healthcare and enhancing quality of life.
  • Immunis is excited by the opportunities that this partnership can offer, and we hope to successfully address sarcopenia as a united front.

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

Retrieved on: 
Dienstag, Mai 21, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Inflammation, FDA, Autoimmunity, Sarcopenia, PMCB, Food, Pharmaceutical industry

PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”), today announced a $7 million investment in MyMD Pharmaceuticals, Inc. (Nasdaq:MYMD) (“MyMD”) a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions.

Key Points: 
  • PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”), today announced a $7 million investment in MyMD Pharmaceuticals, Inc. (Nasdaq:MYMD) (“MyMD”) a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions.
  • PharmaCyte’s investment in externally developed technology solidifies its strategy to prudently apply its approximately $65 million (as of March 31, 2024) cash position.
  • We are looking forward to potential collaboration with PharmaCyte, as its management and board have extensive experience in the public biotechnology markets.
  • MyMD’s approach to inflammation is unlike what is currently available and addresses significant unmet medical needs in this category.

MyMD Pharmaceuticals Secures Strategic Investments

Retrieved on: 
Dienstag, Mai 21, 2024
Biotechnology, Health, Science, Other Science, Pharmaceutical, Diabetes, Regulation D, Exercise, Sarcopenia, Sale, Ageing, Cancer, Autoimmunity, PMCB, Rheumatoid arthritis, Security (finance)

MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, and autoimmune and inflammatory conditions, today announced that it has secured $7 million in commitments in two private placement funding rounds led by a strategic investor, PharmaCyte Biotech, Inc. (Nasdaq: PMCB), a clinical-stage biotechnology company developing cellular therapies for cancer and diabetes.

Key Points: 
  • MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, and autoimmune and inflammatory conditions, today announced that it has secured $7 million in commitments in two private placement funding rounds led by a strategic investor, PharmaCyte Biotech, Inc. (Nasdaq: PMCB), a clinical-stage biotechnology company developing cellular therapies for cancer and diabetes.
  • An additional $7 million was raised from existing MyMD shareholders participating in the offerings.
  • The closings of the two private placements are each subject to customary closing conditions and are both expected to occur on or around May 22, 2024.
  • “We are excited to welcome PharmaCyte as a new strategic investment partner in our continuing development of MYMD-1 in sarcopenia, as well as the evaluation of our other approved INDs in rheumatoid arthritis (RA) and Hashimoto’s thyroiditis,” said Chris Chapman, M.D., President, Chief Medical Officer, and Director of MyMD.

BioAge Labs Announces Inaugural Scientific Advisory Board to Support Advancement of Novel Therapeutics Targeting Metabolic Aging

Retrieved on: 
Mittwoch, Mai 15, 2024
Cardiology, Biotechnology, Other Health, Health, General Health, Seniors, Pharmaceutical, Research, Genetics, Consumer, Science, GLP1R, Diabetes, Biology, MASH, Translational medicine, Obesity, Metformin, Drug development, GSK, FACP, Senior, Harvard Medical School, Body composition, Inflammation, Geriatrics, Type 2 diabetes, The Obesity Society, DSM-IV codes, Sarcopenia, Publication, Ageing, Duke University, FGF21, Internal medicine, Clinical trial, PCSK9, Associate, Human nutrition, Weight loss, SAB, Obesity medicine, Patient, UC, Amgen, Exercise, Therapy, Longevity, Apelin, University of California, Berkeley, Pharmaceutical industry

BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic candidates for metabolic diseases, such as obesity, by targeting the biology of aging, today announced the formation of its Scientific Advisory Board (SAB).

Key Points: 
  • BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic candidates for metabolic diseases, such as obesity, by targeting the biology of aging, today announced the formation of its Scientific Advisory Board (SAB).
  • The SAB is composed of world-renowned leaders with expertise spanning metabolic disease biology, obesity medicine, and clinical development of blockbuster therapeutics.
  • The SAB will work closely with BioAge's leadership team to advance the company's pipeline of novel treatments for age-related chronic metabolic diseases into mid- and late-stage clinical development.
  • “We will also leverage their broad expertise in drug development for metabolic diseases to guide the continued advancement of the other programs in our metabolic disease pipeline.”

BPGbio Brings Late Clinical Stage Rare Disease and Oncology Assets to US and EU Pharma Partnering Summits

Retrieved on: 
Dienstag, Mai 7, 2024
Software, Research, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Neurology, FDA, Health, Breast cancer, Brain, Q10, HPC, Parkinson's disease, Carcinoma, Liver disease, Oak Ridge National Laboratory, State, Pancreatic cancer, Doctor of Philosophy, Tumor microenvironment, GBM, Epidermolysis bullosa, SCC, Therapy, Patient, Sarcopenia, Glioblastoma, Biomarker, Drug discovery, Orphan drug, EB, TME, Pharmaceutical industry

BPGbio’s executives, including Daniel Elliott , Board Member and Chief Commercial Advisor, plan to share details of the company’s commercial ready assets.

Key Points: 
  • BPGbio’s executives, including Daniel Elliott , Board Member and Chief Commercial Advisor, plan to share details of the company’s commercial ready assets.
  • BPM31510 acts by targeting the mitochondrial machinery and tumor microenvironment (TME) to create a metabolic shift in cancer cells, leading to cancer cell death.
  • BPGbio is also exploring a late stage trial with BPM31510-IV/oral for primary coenzyme Q10 deficiency , an ultra-rare, potentially life threatening disease that affects the brain, muscles, and kidneys in afflicted patients.
  • This platform identifies targets, biomarkers, and drugs and assists the development team through both the development and clinical trial stages.

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024

Retrieved on: 
Mittwoch, Mai 8, 2024
Congress, Cirrhosis, Liver disease, EASL, Hepatic encephalopathy, MD, Virginia Commonwealth University, Patient, Sarcopenia

SALT LAKE CITY, May 8, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that data from the Phase 2 study of LPCN 1148 has been selected for a late breaking oral presentation at the European Association for the Study of Liver ("EASL") Congress, to take place June 5 to 8, 2024 in Milan, Italy.

Key Points: 
  • SALT LAKE CITY, May 8, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that data from the Phase 2 study of LPCN 1148 has been selected for a late breaking oral presentation at the European Association for the Study of Liver ("EASL") Congress, to take place June 5 to 8, 2024 in Milan, Italy.
  • Intervention with oral LPCN 1148 improves sarcopenia and hepatic encephalopathy ("HE") in patients with cirrhosis: a 52-week phase 2 randomized clinical trial
    Dr. Arun J. Sanyal, MD, Director, Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University

Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity

Retrieved on: 
Freitag, Mai 3, 2024
FDA, Upjohn, Cytoprotection, Research, Geriatrics, Trial of the century, Doctor of Philosophy, IND, Hepatology, Prostaglandin, Baylor University, SAB, Endocrinology, Baylor College of Medicine, Ageing, Diabetes, Euronext Growth, Gastroenterology, Wellcome Research Laboratories, Obesity, Therapy, Royal Free Hospital, Notifiable disease, Investigational New Drug, OBA, GLP1, Frailty, Consultant, MD, Facial muscles, Digestion, Patient, Metabolism, Sarcopenia, Internal medicine, Pharmaceutical industry

The OBA SAB will guide the company to develop BIO101 (20-hydroxyecdysone) in obesity, in combination with GLP1-RA, and will actively work towards the finalization of the OBA Phase 2 clinical study design.

Key Points: 
  • The OBA SAB will guide the company to develop BIO101 (20-hydroxyecdysone) in obesity, in combination with GLP1-RA, and will actively work towards the finalization of the OBA Phase 2 clinical study design.
  • Biophytis plans to file for an Investigational New Drug (IND) application to start the OBA Phase 2 clinical study in the USA with FDA in the coming weeks.
  • Stanislas Veillet, CEO de Biophytis states: “We are pleased to announce the appointment of Professor Dennis Villareal and Professor Francisco Guarner to the Scientific Advisory Board of the OBA Phase 2 study.
  • We are preparing with the SAB to file for an IND to start the OBA phase 2 clinical study in the coming weeks.”
    The first two members of Biophytis’ new Scientific Advisory Board for the OBA clinical study are:
    at Baylor College of Medicine, Houston, Texas, United States.

MUSCLE CULTIVATION STARTUP PROFUSE-TECHNOLOGY WELCOMES RENOWNED TECHNION PROFESSOR TO ITS SCIENTIFIC ADVISORY BOARD

Retrieved on: 
Montag, April 22, 2024
Diabetes, Biomedical engineering, Weight loss, Research, Duchenne, Weizmann Institute of Science, Obesity, Biomedicine, Therapy, Cachexia, Patient, Tissue engineering, Regenerative medicine, Sarcopenia, Duchenne muscular dystrophy, Faculty, Ageing, Biotechnology, Pharmaceutical industry

YOKNEAM, Israel, April 22, 2024 /PRNewswire/ -- ProFuse Technology expands its scope as a muscle cultivation startup aiming to enhance patient outcomes by improving treatments for muscle associated diseases and muscle regeneration. The company has appointed Professor Shulamit Levenberg of the Technion Faculty of Biomedical Engineering to its Scientific Advisory Board, to support its effort towards life science applications.

Key Points: 
  • YOKNEAM, Israel, April 22, 2024 /PRNewswire/ -- ProFuse Technology expands its scope as a muscle cultivation startup aiming to enhance patient outcomes by improving treatments for muscle associated diseases and muscle regeneration.
  • The company has appointed Professor Shulamit Levenberg of the Technion Faculty of Biomedical Engineering to its Scientific Advisory Board, to support its effort towards life science applications.
  • She has joined ProFuse Technology's Scientific Advisory Board to bolster the company's effort to develop materials and methodologies for muscle regeneration and maintenance.
  • We are thrilled to welcome Professor Levenberg's to our Scientific Advisory Board, in order to bolster our pioneering innovative approaches towards muscle regeneration and maintenance."

Why you shouldn’t be afraid to start running after middle age

Retrieved on: 
Freitag, April 19, 2024
Knee, Atrophy, Pressure, MRI, Osteopenia, Exercise, Walking, Activity, Cell, Bone marrow, Chemical oxygen demand, Risk, Gamer, Research, Sarcopenia, Running, Rest, Joint, Volunteering, Life, Arthritis, Osteoporosis, Spine, Bed rest, Cartilage, Osteoarthritis, Skeleton, Dietary supplement

As someone who started marathon running in mid-life, I know how many aches and pains (and doubts) you can have if you take on the challenge to start running at an older age.

Key Points: 
  • As someone who started marathon running in mid-life, I know how many aches and pains (and doubts) you can have if you take on the challenge to start running at an older age.
  • Hobbling around my orthopaedic hospital after my first marathon actually led me to do research on runners.
  • The high-resolution MRI scans found most of the 115 middle-aged participants had abnormalities in their knees before starting marathon training.
  • But while osteoarthritis is more common after middle age, it may actually be a lack of activity that leads to osteoarthritis.
  • Reduced muscle use, whether it is through inactivity or sarcopenia or both, also reduces the production of anti-inflammatory myokines from the muscles.
  • These chemicals are released when we exercise, and help reduce joint swelling and calm irritated joint linings.
  • This effect is pronounced in runners because running uses some of the largest muscles in the body – such as the glutes, quadriceps and hamstrings.

Where to begin

  • If you want to start running, the main message is to ease into it to reduce the risk of injury.
  • One of the best ways to ease into running in mid-life is the NHS Couch to 5K running programme.
  • It’s a free guide that will help you gradually work up towards running 5km in just nine weeks.
  • If you’ve experienced any of these problems, you’ll want to be careful when exercising to avoid further damage.


Alister Hart receives funding from 3 charities: The Rosetrees Trust, Arthroplasty for Arthritis and The Maurice Hatter Foundation.

Biophytis announces its 2023 financial results and provides an update on its business activities

Retrieved on: 
Mittwoch, April 10, 2024
Annual, Notifiable disease, Annual report, Conference, Obesity, Euronext Growth, Goldman Sachs, Disease, MDA, Partnership, Risk, COVID-19, Patient, Duchenne muscular dystrophy, Sarcopenia, University, Respiratory failure, Clinical trial, Therapy, FDA, Pharmaceutical industry

2024: The actual start of the study will depend on the conclusion of partnership agreements and Biophytis' financial resources.

Key Points: 
  • 2024: The actual start of the study will depend on the conclusion of partnership agreements and Biophytis' financial resources.
  • Promising preclinical results for BIO101 (20-hydroxyecdysone) in obesity, suggesting beneficial metabolic effects on muscle and fat mass.
  • On this basis, Biophytis plans to start a phase 1/2 clinical trial in 2024, depending on its financial resources.
  • There is therefore significant doubt about the Company's ability to continue its business activities.